<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4809">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444128</url>
  </required_header>
  <id_info>
    <org_study_id>IMPReSSION Study</org_study_id>
    <nct_id>NCT04444128</nct_id>
  </id_info>
  <brief_title>IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION</brief_title>
  <acronym>IMPReSSION</acronym>
  <official_title>IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kerckhoff Klinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic properties of myocardial tissue change in the presence of disease. This is&#xD;
      detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping&#xD;
      using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable&#xD;
      imaging measures for myocardial tissue characterisation. Despite similar principles the&#xD;
      measurements differ considerably between different sequences, vendors and field strengths,&#xD;
      yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy&#xD;
      and prognostic relationships in apparently healthy subjects with no known heart disease. A&#xD;
      further unknown relates to separation between healthy myocardium and the subclinical disease&#xD;
      in several groups of patients with suspected cardiac involvement. Examples include patients&#xD;
      with systemic inflammatory conditions, as well as patients with a recent COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Anticipated">November 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 year</time_frame>
    <description>number of deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
    <description>number of deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Outcome</measure>
    <time_frame>1 year and 5 years</time_frame>
    <description>Number of participants with events including death due to heart failure and and hospitalisation due to Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Outcome</measure>
    <time_frame>1 year and 5 years</time_frame>
    <description>Number of participants with death due to myocardial infarction, heart failure, arrhythmia or vascular events (pulmonary embolism, aortic dissection, stroke)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia Outcome</measure>
    <time_frame>1 year and 5 years</time_frame>
    <description>Number of participants with documented events including sudden cardiac death, appropriate ICD discharge, sustained VT</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Myocarditis</condition>
  <condition>Heart Failure</condition>
  <condition>Myocardial Fibrosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CMR with T1 and T2 mapping</intervention_name>
    <description>Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg): T1 and T2 mapping, volumes, function, strain and LGE is performed.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are consecutive asymptomatic healthy subjects or patients from subgroups with&#xD;
        known high risk (such as a recent COVID19 infection) with no known or clinically relevant&#xD;
        cardiac disease or currently prescribed cardiac medication.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide informed consent&#xD;
&#xD;
          2. 18 years of age and over&#xD;
&#xD;
          3. Absence of a valid clinical indication for CMR, including active cardiac symptoms&#xD;
             and/or known or clinically relevant cardiac disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  accepted contraindications for a contrast-enhanced CMR study (in line with MRI safety&#xD;
             and SmPC for contrast agent)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kerckhoff Hospital</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rolf, MD</last_name>
      <email>A.Rolf@kerckhoff-klinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>Frankfurt am Main</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina O Puentmann, MD, PhD</last_name>
      <phone>+4969186760</phone>
      <email>cvi-research@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Weis</last_name>
      <phone>+4969630184454</phone>
      <email>cvi-research@kgu.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Hessen</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Wenzel, MD</last_name>
      <email>wenzelp@uni-mainz.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.cardiac-imaging.org/impression-study.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Valentina Puentmann</investigator_full_name>
    <investigator_title>Priv Doz Dr Dr</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

